www.IBN-is.com

A*STAR Outstanding Publications Award 2009, 2010, 2012, 2013 and 2014
A*STAR Patent Power Award 2009 and 2010
Singapore HEALTH Award (Platinum) 2012, (Gold) 2008 and 2010

ISO Certified (ISO 9001:2008)

OHSAS Certified (SS 506 Part 1:2009/ BS OHSAS 18001:2007

INNOVATIONS FOR TOMORROW

Announcements

Nano Today on World’s Top 5 List in Three Journal Categories
Singapore-based journal records its highest impact factor of 18.432

August 13, 2014 – Singapore-based Nano Today journal has received a record high impact factor of 18.432 in 2013, up from 17.689 in 2012, according to the Journal Citation Reports® published by Thomson Reuters last month. The scientific journal is one of the highest impact publications across nanoscience and nanotechnology, materials science and chemistry.

Nano Today ranks 2nd among 73 journals in the Nanoscience and Nanotechnology category, 4th out of 251 journals in Materials Science (Multidisciplinary), and 5th out of 148 journals in Chemistry (Multidisciplinary). Nano Today is also the only Asia-based journal among the top 5 journals in these disciplines.

Nano Today is committed towards furthering the latest advances in the multidisciplinary field of nanoscience and nanotechnology, and I am delighted that it is recognized for publishing high-impact and high-quality articles. The journal’s high citation illustrates the importance of our papers in this competitive, rapidly evolving field. I would like to thank our readers, authors, reviewers, Editorial Advisory Board and our Managing Editor Noreena AbuBakar for their strong support and contributions to the journal’s success,” said Professor Jackie Y. Ying, Editor-in-Chief of Nano Today, who is also the Executive Director of the Institute of Bioengineering and Nanotechnology, Singapore.

Read more.

Taking the Guesswork out of Cancer Therapy
New molecular test kit predicts patient’s survival and drug response


Some members of the research team (clockwise from bottom left): IBN Postdoctoral Fellows Dr. Yukti Choudhury and Dr. Xiaona Wei, SGH Dept. of Pathology, Head and Senior Consultant, Prof. Tan Puay Hoon, NCCS Consultant Dr. Ravindran Kanesvaran, IBN Team Leader and Principal Research Scientist Dr. Min-Han Tan.

August 1, 2014 – Researchers and doctors at the Institute of Bioengineering and Nanotechnology (IBN), Singapore General Hospital (SGH) and National Cancer Centre Singapore (NCCS) have co-developed the first molecular test kit that can predict treatment and survival outcomes in kidney cancer patients. This breakthrough was recently reported in European Urology, the world’s top urology journal.

According to IBN Executive Director Professor Jackie Y. Ying, “By combining our expertise in molecular diagnostics and cancer research, we have developed the first genetic test to help doctors prescribe the appropriate treatment for kidney cancer patients based on their tumor profile.”

Dr. Min-Han Tan, who is IBN Team Leader and Principal Research Scientist and a visiting consultant at the Division of Medical Oncology NCCS, shared his motivation, “As a practicing oncologist, I have cared for many patients with kidney cancer. I see the high costs of cancer care, the unpredictable outcomes and occasional futility of even the best available drugs. This experience inspired our development of this assay to improve all these for patients.”

Read more.

Polycarbonates to Tackle Multidrug Resistance
Polymers that can be fine-tuned for optimal effect could help fight multidrug-resistant infections


Scanning electron microscopy images of Escherichia coli before (top) and after (bottom) two-hour treatment with a polymer. The treated E. coli cells show distorted and corrugated surfaces compared to the intact control cells.
Reproduced, with permission, from Ref. 1 © 2013 American Chemical Society

July 2, 2014 – The rise of drug-resistant microbes is a major challenge facing medicine. The World Health Organization’s 2014 report on global surveillance of antimicrobial resistance warns of the very real possibility of the twenty-first century becoming “a post-antibiotic era – in which common infections and minor injuries can kill”. In the face of this threat, researchers worldwide are exploring approaches to find new compounds that combine selective antimicrobial efficacy with low toxicity toward mammalian cells.

Dr Yi Yan Yang at the Institute of Bioengineering and Nanotechnology and co-workers have now created a range of large polycarbonate molecules that are potent antimicrobials and are tolerated well by rat red blood cells, suggesting that they could prove similarly effective in humans. Crucially, by subtly varying the composition of the polycarbonate molecules, the researchers could fine-tune the selectivity and activity of these candidate drugs.

Read more.

More   

IBN in the News

Polycarbonates to Tackle Multidrug Resistance
A*STAR Research, 02 Jul 2014

Finetuning Polycarbonates to Tackle Multidrug resistance
Nanowerk, 02 Jul 2014

A Charged Partnership
Asian Scientist, 01 Jul 2014

More News   

EVENTS

2014
8 Dec - 9 Dec
2nd IBN International Symposium – Nanomedicine and Nanoassays

Event Calendar   

FEATURED PUBLICATIONS

A Multigene Assay Identifying Distinct Prognostic Subtypes of Clear Cell Renal Cell Carcinoma with Differential Response to Tyrosine Kinase Inhibition
European Urology, (2014)
DOI: 10.1016/j.eururo.2014.06.041.
(IF: 10.476) article

Overcoming Multidrug Resistance in Microbials Using Nanostructures Self-Assembled from Cationic Bent-Core Oligomers
Small, (2014)
DOI: 10.1002/smll.201303921.
(IF: 7.823) article

Palladium Nanomaterials in Catalytic Intramolecular C–H Amination Reactions
Chemical Communications, (2014)
DOI: 10.1039/c4cc03551h.
(IF: 6.378) article

More   

JOIN US!

Research Positions

Facilities and Safety Positions

Corporate Administration Positions

Institute of Bioengineering and Nanotechnology   31 Biopolis Way, The Nanos, #04-01, Singapore 138669   Tel: +65 6824 7000   Fax: +65 6478 9080   Email: enquiry@ibn.a-star.edu.sg   |   View IBN Privacy Statement